NCT06402708View on ClinicalTrials.gov

Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

PHASE3RecruitingINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2030

Conditions
Thymic Carcinoma
Interventions
DRUG

Chemotherapy

paclitaxel 60mg/m2, ivgtt; cisplatin 30mg/m2, ivgtt; 5-FU 500mg/m2, ivgtt and 500mg/m2, civ 24h; calcium folinate 200mg; q3w.

RADIATION

Radiotherapy

IMRT, 50Gy/25f

Trial Locations (1)

212013

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER